CHAIRED BY:
Philip Hewitt, UK and Eurotox Registered Toxicologist, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA
Stefan Przyborski, Professor of Cell Technology, Durham university
Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.
SMi鈥檚 3D Cell Culture Conference will explore advances of organ and lab-on-a-chip, microphysiological systems, applications of technology and case studies, imaging, high throughput screening and advances in 3D cell culture models which make up core components within the 3D Cell Culture field.
Bioprinting has become increasingly efficient and accurate in building in vitro tissue models with the potential to provide pathologically relevant responses and model human disease mechanisms. Bio-printed structures yield phenotypic endpoints that are comparable with clinical studies and can provide a realistic prediction of clinical efficacy. The use of bioprinting is growing in big pharma companies as an alternative to organ-on-a-chip systems.
For the first time ever the NEW 3D Bioprinting Focus Day on 18 February 2020 will explore case studies from big pharma, biotech鈥檚 and academia exploring how bioprinting is being used in industry highlighting projects looking at stem cell therapy, drug screening and extracellular matrix scaffolds.
WHO SHOULD ATTEND?
Biotech / Pharma Companies - Team Leader, Junior Principle investigator, Cell and Molecular Scientist, Chief Scientific Officer, Deputy Director, Manager, Founder, CEO, Head, Director, Programme Manager, Lab Head, Toxicologist
Academia Professor - Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering
Solution Providers 鈥� Manager, Head of, CEO, Director, Founder, Account Manager, President, CSO, Executive, Managing Director
Philip Hewitt, UK and Eurotox Registered Toxicologist, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA
Stefan Przyborski, Professor of Cell Technology, Durham university
Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.
SMi鈥檚 3D Cell Culture Conference will explore advances of organ and lab-on-a-chip, microphysiological systems, applications of technology and case studies, imaging, high throughput screening and advances in 3D cell culture models which make up core components within the 3D Cell Culture field.
Bioprinting has become increasingly efficient and accurate in building in vitro tissue models with the potential to provide pathologically relevant responses and model human disease mechanisms. Bio-printed structures yield phenotypic endpoints that are comparable with clinical studies and can provide a realistic prediction of clinical efficacy. The use of bioprinting is growing in big pharma companies as an alternative to organ-on-a-chip systems.
For the first time ever the NEW 3D Bioprinting Focus Day on 18 February 2020 will explore case studies from big pharma, biotech鈥檚 and academia exploring how bioprinting is being used in industry highlighting projects looking at stem cell therapy, drug screening and extracellular matrix scaffolds.
WHO SHOULD ATTEND?
Biotech / Pharma Companies - Team Leader, Junior Principle investigator, Cell and Molecular Scientist, Chief Scientific Officer, Deputy Director, Manager, Founder, CEO, Head, Director, Programme Manager, Lab Head, Toxicologist
Academia Professor - Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering
Solution Providers 鈥� Manager, Head of, CEO, Director, Founder, Account Manager, President, CSO, Executive, Managing Director
